NC
TSHA icon

nVerses Capital’s Taysha Gene Therapies TSHA Stock Holding History

nVerses Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Buy
+25,152
New +$149K 0.26% 206

Other funds holding TSHA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

nVerses Capital's TSHA Position: Q2 2026 in Review

nVerses Capital opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 25,152 shares worth $171K. The stake represents 0.26% of the portfolio and ranks #206 among its holdings.

131 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • nVerses Capital held 25,152 shares of Taysha Gene Therapies worth $171K as of Q2 2026.
  • Taysha Gene Therapies was a new nVerses Capital position in Q2 2026.
  • Taysha Gene Therapies made up 0.26% of nVerses Capital's portfolio in Q2 2026, its #206 holding.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.